



Financial Tear Sheet

Corporate Profile

ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation).

Primary IR Contact

Barbara Ryan

Partner

Claremont Partners

Phone: (203) 274-2825

E-mail:

bryan@clermontpartners.com

Stock Information

CFRXZ (Warrant to purchase common stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$1.02
Change (%)	▲ 0.08 (8.51%)
Volume	176,225
52 Week Low	\$0.80
Market Cap	\$75,129,126
Rolling EPS	-0.49
PE Ratio	0
Shares Outstanding	73,656,006

Data as of 09/18/17 4:00 p.m. ET



Recent Press Releases & Events

09/13/17 - 7:01 a.m.

[ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference](#)

09/11/17 - 7:01 a.m.

[ContraFect to Present at 2017 World Antimicrobial Resistance Congress](#)

08/09/17 - 7:00 a.m.

[ContraFect Announces Second Quarter 2017 Financial Results](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/18/17	3
08/18/17	3
08/17/17	SC 13G
08/09/17	SC 13G/A

Management

Julia P. Gregory	Chief Executive Officer
Cara Cassino	Chief Medical Officer
Dr. Michael Wittekind, Ph.D.	Chief Scientific Officer and Sr. Vice President, Research
Daniel Couto	Senior Vice President, Manufacturing & Facilities Operations
Josh Muntner	Sr. VP, Business Development
Nancy Dong	Vice President, Controller
Michael Messinger, CPA	Vice President, Finance
Natalie Bogdanos	General Counsel and Corporate Secretary

Data provided by Nasdaq. Minimum 15 minutes delayed.